170 related articles for article (PubMed ID: 37339341)
1. Integrating 3HP-based tuberculosis preventive treatment into Zimbabwe's Fast Track HIV treatment model: experiences from a pilot study.
Mapingure MP; Zech JM; Hirsch-Moverman Y; Msukwa M; Howard AA; Makoni T; Gwanzura C; Apollo T; Sandy C; Musuka GN; Rabkin M
J Int AIDS Soc; 2023 Jun; 26(6):e26105. PubMed ID: 37339341
[TBL] [Abstract][Full Text] [Related]
2. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
Semitala FC; Kadota JL; Musinguzi A; Nabunje J; Welishe F; Nakitende A; Akello L; Bishop O; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PPJ; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
PLoS Med; 2021 Dec; 18(12):e1003875. PubMed ID: 34914696
[TBL] [Abstract][Full Text] [Related]
3. Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives.
Semitala FC; Musinguzi A; Ssemata J; Welishe F; Nabunje J; Kadota JL; Berger CA; Katamba A; Kiwanuka N; Kamya MR; Dowdy D; Cattamanchi A; Katahoire AR
Implement Sci Commun; 2021 Jun; 2(1):71. PubMed ID: 34193311
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.
Semitala FC; Kadota JL; Musinguzi A; Welishe F; Nakitende A; Akello L; Kunihira Tinka L; Nakimuli J; Ritar Kasidi J; Bishop O; Nakasendwa S; Baik Y; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PP; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
PLoS Med; 2024 Feb; 21(2):e1004356. PubMed ID: 38377166
[TBL] [Abstract][Full Text] [Related]
5. Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda.
Kadota JL; Musinguzi A; Nabunje J; Welishe F; Ssemata JL; Bishop O; Berger CA; Patel D; Sammann A; Katahoire A; Nahid P; Belknap R; Phillips PPJ; Namusobya J; Kamya M; Handley MA; Kiwanuka N; Katamba A; Dowdy D; Semitala FC; Cattamanchi A
Implement Sci; 2020 Aug; 15(1):65. PubMed ID: 32787925
[TBL] [Abstract][Full Text] [Related]
6. Acceptability of Community-Based Tuberculosis Preventive Treatment for People Living with HIV in Zimbabwe.
Msukwa MK; Mapingure MP; Zech JM; Masvawure TB; Mantell JE; Musuka G; Apollo T; Boccanera R; Chingombe I; Gwanzura C; Howard AA; Rabkin M
Healthcare (Basel); 2022 Jan; 10(1):. PubMed ID: 35052280
[TBL] [Abstract][Full Text] [Related]
7. Tuberculosis preventive treatment uptake among people living with HIV during COVID-19 period in Addis Ababa, Ethiopia: a retrospective data review.
Gebreegziabher SB; Ashuro AA; Kumssa TH; Teferi MY; Alemayue EA; Datiko DG; Yimer SA; Shagre MB
BMC Infect Dis; 2024 May; 24(1):499. PubMed ID: 38760665
[TBL] [Abstract][Full Text] [Related]
8. Scale-Up of Rifapentine and Isoniazid for Tuberculosis Prevention Among Household Contacts in 2 Urban Centers: An Effectiveness Assessment.
Hussain H; Jaswal M; Farooq S; Safdar N; Madhani F; Noorani S; Shahbaz SS; Salahuddin N; Amanullah F; Khowaja S; Manzar S; Shah JA; Islam Z; Dahri AA; Shahzad M; Keshavjee S; Becerra MC; Khan AJ; Malik AA
Clin Infect Dis; 2023 Aug; 77(4):638-644. PubMed ID: 37083926
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the uptake of tuberculosis preventative therapy for people living with HIV in Namibia: a multiple methods analysis.
Roscoe C; Lockhart C; de Klerk M; Baughman A; Agolory S; Gawanab M; Menzies H; Jonas A; Salomo N; Taffa N; Lowrance D; Robsky K; Tollefson D; Pevzner E; Hamunime N; Mavhunga F; Mungunda H
BMC Public Health; 2020 Dec; 20(1):1838. PubMed ID: 33261569
[TBL] [Abstract][Full Text] [Related]
10. Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania.
Hunter OF; Kyesi F; Ahluwalia AK; Daffé ZN; Munseri P; von Reyn CF; Adams LV
BMC Infect Dis; 2020 Oct; 20(1):738. PubMed ID: 33028260
[TBL] [Abstract][Full Text] [Related]
11. Integrating isoniazid preventive therapy into the fast-track HIV treatment model in urban Zambia: A proof-of -concept pilot project.
Mukumbwa-Mwenechanya M; Mubiana M; Somwe P; Zyambo K; Simwenda M; Zongwe N; Kalunkumya E; Mwango LK; Rabkin M; Mpesela F; Chungu F; Mwanza F; Preko P; Bolton-Moore C; Bosomprah S; Sharma A; Morton K; Kasonde P; Mulenga L; Lingu P; Mulenga PL
PLOS Glob Public Health; 2023; 3(3):e0000909. PubMed ID: 36962979
[TBL] [Abstract][Full Text] [Related]
12. New opportunities in tuberculosis prevention: implications for people living with HIV.
González Fernández L; Casas EC; Singh S; Churchyard GJ; Brigden G; Gotuzzo E; Vandevelde W; Sahu S; Ahmedov S; Kamarulzaman A; Ponce-de-León A; Grinsztejn B; Swindells S
J Int AIDS Soc; 2020 Jan; 23(1):e25438. PubMed ID: 31913556
[TBL] [Abstract][Full Text] [Related]
13. Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe.
Nyathi S; Dlodlo RA; Satyanarayana S; Takarinda KC; Tweya H; Hove S; Matambo R; Mandewo W; Nyathi K; Sibanda E; Harries AD
PLoS One; 2019; 14(10):e0223076. PubMed ID: 31581271
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.
Mathad JS; Savic R; Britto P; Jayachandran P; Wiesner L; Montepiedra G; Norman J; Zhang N; Townley E; Chakhtoura N; Bradford S; Patil S; Popson S; Chipato T; Rouzier V; Langat D; Chalermchockcharoentkit A; Kamthunzi P; Gupta A; Dooley KE
Clin Infect Dis; 2022 May; 74(9):1604-1613. PubMed ID: 34323955
[TBL] [Abstract][Full Text] [Related]
15. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.
Scriba TJ; Fiore-Gartland A; Penn-Nicholson A; Mulenga H; Kimbung Mbandi S; Borate B; Mendelsohn SC; Hadley K; Hikuam C; Kaskar M; Musvosvi M; Bilek N; Self S; Sumner T; White RG; Erasmus M; Jaxa L; Raphela R; Innes C; Brumskine W; Hiemstra A; Malherbe ST; Hassan-Moosa R; Tameris M; Walzl G; Naidoo K; Churchyard G; Hatherill M;
Lancet Infect Dis; 2021 Mar; 21(3):354-365. PubMed ID: 33508224
[TBL] [Abstract][Full Text] [Related]
16. Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis.
Uppal A; Rahman S; Campbell JR; Oxlade O; Menzies D
PLoS Med; 2021 Sep; 18(9):e1003712. PubMed ID: 34520463
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis.
Yanes-Lane M; Ortiz-Brizuela E; Campbell JR; Benedetti A; Churchyard G; Oxlade O; Menzies D
PLoS Med; 2021 Sep; 18(9):e1003738. PubMed ID: 34520459
[TBL] [Abstract][Full Text] [Related]
18. Implementing 3HP vs. IPT as TB preventive treatment in Pakistan.
Jaswal M; Farooq S; Madhani F; Noorani S; Salahuddin N; Amanullah F; Khowaja S; Safdar N; Khan A; Yuen C; Keshavjee S; Becerra M; Hussain H; Malik AA
Int J Tuberc Lung Dis; 2022 Aug; 26(8):741-746. PubMed ID: 35898140
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
[TBL] [Abstract][Full Text] [Related]
20. Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3 months weekly isoniazid-rifapentine.
Chaisson LH; Semitala FC; Nangobi F; Steinmetz S; Marquez C; Armstrong DT; Opira B; Kamya MR; Phillips PPJ; Dowdy DW; Yoon C
AIDS; 2023 Jun; 37(7):1097-1101. PubMed ID: 36779500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
